MedTrace Logo

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

NCT01410201 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-07-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic epiretinal membrane (ERM).

Conditions

  • Epiretinal Membrane
  • Macular Edema

Interventions

DRUG

Dexamethasone Intravitreal Implant

Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Barnes Retina Institute

    lead OTHER

Principal Investigators

  • Gaurav K Shah, MD · Retina Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01410201 on ClinicalTrials.gov